Mark Temper

495 total citations
15 papers, 177 citations indexed

About

Mark Temper is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mark Temper has authored 15 papers receiving a total of 177 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 6 papers in Cancer Research and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mark Temper's work include Cancer Genomics and Diagnostics (5 papers), Colorectal Cancer Treatments and Studies (4 papers) and Genetic factors in colorectal cancer (3 papers). Mark Temper is often cited by papers focused on Cancer Genomics and Diagnostics (5 papers), Colorectal Cancer Treatments and Studies (4 papers) and Genetic factors in colorectal cancer (3 papers). Mark Temper collaborates with scholars based in Israel, United States and Russia. Mark Temper's co-authors include Tamar Peretz, Azzam Salah, Ayala Hubert, Beatrice Uziely, Esther Tahover, Ilya Tsimafeyeu, Meir Liebergall, Rami Mosheiff, Tamar Hamburger and Amos Peyser and has published in prestigious journals such as Journal of Clinical Oncology, Nature Biotechnology and Cancer Research.

In The Last Decade

Mark Temper

14 papers receiving 174 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark Temper Israel	8	69	61	46	38	36	15	177
Michele Ly United States	6	50 0.7×	44 0.7×	42 0.9×	44 1.2×	47 1.3×	16	166
Giovanni Savarese Italy	10	86 1.2×	80 1.3×	46 1.0×	46 1.2×	29 0.8×	43	250
Marco Schupp United States	8	96 1.4×	46 0.8×	20 0.4×	43 1.1×	23 0.6×	17	175
Monirath Hav United States	8	102 1.5×	57 0.9×	25 0.5×	28 0.7×	51 1.4×	18	208
M Tan Singapore	7	40 0.6×	112 1.8×	52 1.1×	51 1.3×	25 0.7×	9	182
Silvana Acquafredda Italy	6	159 2.3×	42 0.7×	40 0.9×	94 2.5×	24 0.7×	8	237
Yakup Ergün Türkiye	7	122 1.8×	30 0.5×	62 1.3×	58 1.5×	24 0.7×	44	181
Haijun Tang China	10	46 0.7×	69 1.1×	55 1.2×	43 1.1×	52 1.4×	28	226
Connor Lynch United States	5	81 1.2×	44 0.7×	45 1.0×	65 1.7×	21 0.6×	14	213
Angelo Dipasquale Italy	9	66 1.0×	55 0.9×	46 1.0×	36 0.9×	15 0.4×	23	217

Countries citing papers authored by Mark Temper

Since Specialization

Citations

This map shows the geographic impact of Mark Temper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Temper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Temper more than expected).

Fields of papers citing papers by Mark Temper

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Temper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Temper. The network helps show where Mark Temper may publish in the future.

Co-authorship network of co-authors of Mark Temper

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Temper. A scholar is included among the top collaborators of Mark Temper based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Temper. Mark Temper is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Jain, Suyog, Shaheenah Dawood, Dan Aderka, et al.. (2024). Utilization of tissue-free minimal residual disease testing in colorectal cancer patients from Asia and Middle East. Frontiers in Oncology. 14. 1426941–1426941.

Furth, Noa, Ekaterina N. Andreishcheva, Daniel Jones, et al.. (2022). Multiplexed, single-molecule, epigenetic analysis of plasma-isolated nucleosomes for cancer diagnostics. Nature Biotechnology. 41(2). 212–221. 56 indexed citations

Tsimafeyeu, Ilya & Mark Temper. (2021). Cholangiocarcinoma: An Emerging Target for Molecular Therapy. PubMed. 8(4). 153–158. 11 indexed citations

Nevo, Yuval, Gillian Kay, Mark Temper, et al.. (2020). Splicing Factor Transcript Abundance in Saliva as a Diagnostic Tool for Breast Cancer. Genes. 11(8). 880–880. 7 indexed citations

Zick, Aviad, Tamar Peretz, Michal Lotem, et al.. (2017). Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients. Medicine. 96(20). e6931–e6931. 3 indexed citations

Purim, Ofer, Alexander Beny, Moshe Inbar, et al.. (2017). Molecular profiling-selected treatment in metastatic gastric and oesophageal cancer: Real-life clinical experience.. Journal of Clinical Oncology. 35(15_suppl). e15537–e15537. 2 indexed citations

Zick, Aviad, Tamar Peretz, Michal Lotem, et al.. (2016). Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients. Annals of Oncology. 27. vi26–vi26. 1 indexed citations

Temper, Mark, Alex Beny, Abed Khalaileh, et al.. (2015). Management of Inguinal Involvement of Peritoneal Surface Malignancies by Cytoreduction and HIPEC with Inguinal Perfusion. Journal of Cancer. 6(3). 243–246. 1 indexed citations

Epelbaum, Ron, Einat Shacham‐Shmueli, Baruch Klein, et al.. (2015). Molecular Profiling-Selected Therapy for Treatment of Advanced Pancreaticobiliary Cancer: A Retrospective Multicenter Study. BioMed Research International. 2015. 1–9. 7 indexed citations

10.

Tahover, Esther, Ayala Hubert, Mark Temper, et al.. (2014). An observational cohort study of bevacizumab and chemotherapy in metastatic colorectal cancer patients: safety and efficacy with analysis by age group. Targeted Oncology. 10(1). 55–63. 18 indexed citations

11.

Tahover, Esther, Beatrice Uziely, Azzam Salah, et al.. (2012). Hypertension as a predictive biomarker in bevacizumab treatment for colorectal cancer patients. Medical Oncology. 30(1). 327–327. 37 indexed citations

12.

Tahover, Esther, Beatrice Uziely, Mark Temper, et al.. (2012). P-0214 Hypertension as A Predictive Biomarker in Bevacizumab. Annals of Oncology. 23. iv91–iv91. 1 indexed citations

13.

Katz, Daniela, Tamar Hamburger, Mark Temper, et al.. (2009). Fertility and pregnancy in patients below the age of 35 following chemotherapy for breast cancer.. Cancer Research. 69(2_Supplement). 6148–6148. 1 indexed citations

14.

Kadouri, Luna, Mark Temper, Tal Grenader, et al.. (2008). Absence of founder BRCA1 and BRCA2 mutations in coetaneous malignant melanoma patients of Ashkenazi origin. Familial Cancer. 8(1). 29–32. 9 indexed citations

15.

Ateşok, Kıvanç, et al.. (2007). Treatment of Pathological Humeral Shaft Fractures with Unreamed Humeral Nail. Annals of Surgical Oncology. 14(4). 1493–1498. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact